open access

Vol 65, No 2 (2015)
Research paper (original)
Published online: 2015-05-06
Get Citation

The content of this article is also available in the following languages:
Polski

Evaluation of the prognostic value of the expression of a combination of selected biomarkers in patients with cervical cancer treated with radiotherapy and cisplatin

Małgorzata Klimek
DOI: 10.5603/NJO.2015.0022
·
Nowotwory. Journal of Oncology 2015;65(2):111-121.

open access

Vol 65, No 2 (2015)
Original article
Published online: 2015-05-06

Abstract

Aim. The aim of this study was to evaluate the prognostic significance of the expression of selected biomarkers in patients with inoperable cancer of the cervix treated with irradiation only or irradiation and cisplatin.

Material and methods. The retrospective analysis included 186 patients who were treated between 2003 and 2008. Histological evaluation took into consideration parameters such as histological type, the presence of atypical mitosis and mitotic index. In the assessment of EGFR expression, COX-2, Bax, Bcl2, P16, two domains of P53, Ki-67, and vascular endothelial cell antigen CD34 the immunohistochemical method was used. The importance of ploidy of tumour cells and the S phase and S+G2M phase fractions and the percentage of aneuploid cells in the flow cyto­fluorimeter has been assessed. The influence of prognostic significance of EGFR gene amplification by the FISH test has been assessed. The importance of SCC antigen level after treatment was also analysed.

Results. In univariate analysis the following factors had an influence on DFS: age, total treatment time (as continuous variables), FIGO stage and Hb levels before and during treatment. The following markers beyond the established cut-off, had a significant, adverse effect on DFS: Ki-67, MI, S+G2M phase cells fraction, fraction of aneuploid cells and presence of atypical mitosis. Also, the lack of normalisation of SCC-Ag level after oncological treatment appeared to be a significant prognostic factor. In multivariate analysis, increased risk of recurrence, metastatic spread or death, affected patients whose tumour was characterised by microvessel density and expression of Ki-67 exceeding the established cut-off points, and patients with elevated the SCC-Ag level after the completion of oncological treatment. The importance of SCC antigen level after oncological treatment was also analysed.

Conclusions. 1. The analysis confirmed the importance of the classical prognostic factors: FIGO stage, total treat­ment time and age. 2. Information about microvessel density and Ki-67 expression in the primary tumour before treatment as well as the level of SCC-Ag after completion of oncological treatment are helpful in assessing the risk of treatment failure.

Abstract

Aim. The aim of this study was to evaluate the prognostic significance of the expression of selected biomarkers in patients with inoperable cancer of the cervix treated with irradiation only or irradiation and cisplatin.

Material and methods. The retrospective analysis included 186 patients who were treated between 2003 and 2008. Histological evaluation took into consideration parameters such as histological type, the presence of atypical mitosis and mitotic index. In the assessment of EGFR expression, COX-2, Bax, Bcl2, P16, two domains of P53, Ki-67, and vascular endothelial cell antigen CD34 the immunohistochemical method was used. The importance of ploidy of tumour cells and the S phase and S+G2M phase fractions and the percentage of aneuploid cells in the flow cyto­fluorimeter has been assessed. The influence of prognostic significance of EGFR gene amplification by the FISH test has been assessed. The importance of SCC antigen level after treatment was also analysed.

Results. In univariate analysis the following factors had an influence on DFS: age, total treatment time (as continuous variables), FIGO stage and Hb levels before and during treatment. The following markers beyond the established cut-off, had a significant, adverse effect on DFS: Ki-67, MI, S+G2M phase cells fraction, fraction of aneuploid cells and presence of atypical mitosis. Also, the lack of normalisation of SCC-Ag level after oncological treatment appeared to be a significant prognostic factor. In multivariate analysis, increased risk of recurrence, metastatic spread or death, affected patients whose tumour was characterised by microvessel density and expression of Ki-67 exceeding the established cut-off points, and patients with elevated the SCC-Ag level after the completion of oncological treatment. The importance of SCC antigen level after oncological treatment was also analysed.

Conclusions. 1. The analysis confirmed the importance of the classical prognostic factors: FIGO stage, total treat­ment time and age. 2. Information about microvessel density and Ki-67 expression in the primary tumour before treatment as well as the level of SCC-Ag after completion of oncological treatment are helpful in assessing the risk of treatment failure.

Full Text:

View HTML
Get Citation
About this article
Title

Evaluation of the prognostic value of the expression of a combination of selected biomarkers in patients with cervical cancer treated with radiotherapy and cisplatin

Journal

Nowotwory. Journal of Oncology

Issue

Vol 65, No 2 (2015)

Article type

Research paper (original)

Pages

111-121

Published online

2015-05-06

Page views

977

Article views/downloads

2088

DOI

10.5603/NJO.2015.0022

Bibliographic record

Nowotwory. Journal of Oncology 2015;65(2):111-121.

Authors

Małgorzata Klimek

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl